Sucralan 1g/5ml

Quick links

Choose a section

Quick links to important sections

Advertisements

Sucralan 1g/5ml

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Sucralan 1g/5ml

Property Description
Active Ingredient Sucralfate
Form Oral Suspension (Liquid)
Pharmacological Class Antiulcer Agent / Mucosal Protectant
General Purpose Protection and healing of damaged gastrointestinal lining
Origin Synthetic derivative (Aluminum Complex)

Sucralan 1g/5ml is an oral, prescription-only medication formulated as an Oral Suspension, which belongs to the pharmacological class of Antiulcer Agents and Gastrointestinal Protectants. The active ingredient is Sucralfate, present at a concentration of one gram per five milliliters, establishing it as a high-strength liquid preparation. Sucralfate is a synthetic derivative—specifically an aluminum complex of sulfated sucrose—designed to deliver its therapeutic effect locally within the upper digestive system with minimal absorption into the bloodstream. This localized action results in a non-systemic nature.

The essential therapeutic purpose of Sucralan 1g/5ml is to act as a Mucosal Protectant and a Cytoprotective Agent, helping to shield the inner lining of the esophagus, stomach, and duodenum from continued injury. In the stomach’s acidic environment, the Sucralfate compound rapidly transforms into a viscous, adhesive polyanion gel. This action is distinct from pH alteration, as the primary goal is to form a physical barrier, a mechanism that aids in defense against corrosive digestive factors like acid and pepsin. The resulting ulcer-adherent complex isolates the damaged tissue, which, as a liquid suspension, provides broad, immediate coverage for patients experiencing irritation of the upper gastrointestinal tract.

Regulatory References

  1. Sucralfate Mechanism - StatPearls NIH
Advertisements

What side effects are possible with Sucralan 1g/5ml?

Possible Side Effects and Safety Information

This section details the officially documented adverse effects and safety characteristics of Sucralan (sucralfate oral suspension) as published in government-approved regulatory sources.

Documented Adverse Reactions and Frequencies

The adverse reactions listed in regulatory documents are classified by the likelihood of occurrence, which is typically derived from clinical trial data. Constipation is the most frequently reported side effect.

System Organ Class Adverse Reaction Frequency Classification
Gastrointestinal Disorders Constipation Common (1% to 10%)
Dry mouth, Nausea Uncommon (0.1% to 1%)
Diarrhea, Vomiting, Gastric discomfort Not Known
Nervous System Disorders Headache, Dizziness, Drowsiness Not Known
Skin Disorders Rash, Urticaria Rare or Not Known

Serious Safety Warnings and Restrictions

Administration Restriction

Sucralan is for oral administration only. Serious, potentially fatal complications, including pulmonary and cerebral emboli, have been reported following the inappropriate intravenous (IV) administration of the oral suspension.

Population-Specific Warnings

  • Chronic Renal Impairment: Use with caution. Sucralfate is an aluminum compound, and small amounts of aluminum are absorbed. In patients with severe renal impairment or those undergoing dialysis, aluminum can accumulate, leading to toxicity such as encephalopathy or osteodystrophy, particularly with long-term use.
  • Bezoar Formation: There are reports of bezoar formation (undigested masses that can cause obstruction), primarily in patients with impaired gastric emptying or other predisposing conditions.
  • Hypersensitivity: The medication is contraindicated in patients with known hypersensitivity to sucralfate or its components.
  • Pregnancy and Pediatric Use: Safety and effectiveness have not been established in children, and the product should be used in pregnant women only if clearly needed.
Advertisements

Overdose and Emergency Response

The official regulatory documentation for Sucralan 1g/5ml (Sucralfate) characterizes acute oral overdosage as carrying a minimal risk of severe systemic toxicity. This classification is due to the drug’s fundamental property of being only slightly absorbed into the body. In the rare cases of overconsumption, patients have often remained asymptomatic. When clinical manifestations are reported, they are typically limited to the gastrointestinal system, including nausea, vomiting, abdominal pain, dyspepsia, and constipation.

There are no specific treatment recommendations or known antidotes listed for acute oral overdose; management is generally limited to symptomatic and supportive treatment.

Despite the minimal acute systemic risk, emergency medical attention must be sought immediately if an overdose is suspected. Regulatory guidance mandates that emergency services must be called if the affected individual exhibits severe signs, including seizures, collapse, or trouble breathing.

Population-Specific Overdose Considerations

A distinct, population-specific risk is documented for patients with chronic renal failure or those undergoing dialysis. Due to impaired aluminum excretion, prolonged use can lead to aluminum accumulation and subsequent toxicity, with documented outcomes such as encephalopathy and osteomalacia. Monitoring for aluminum toxicity may be required in this high-risk population.

Advertisements

Therapeutic Uses of Sucralan 1g/5ml

Main Uses of Sucralan 1g/5ml

Sucralan 1g/5ml is an oral suspension containing sucralfate, a medication primarily used to manage and promote the healing of specific gastrointestinal conditions. It belongs to a class of drugs known as cytoprotective agents, which work by forming a physical barrier over damaged tissue.

Treatment of Peptic Ulcers

The primary application of Sucralan is in the treatment of active ulcers located in the stomach (gastric ulcers) and the upper part of the small intestine (duodenal ulcers). By adhering to the site of the ulcer, the medication helps protect the raw tissue from further irritation by gastric acid, pepsin, and bile salts, allowing the natural healing process to occur.

Prevention of Ulcer Recurrence

Beyond treating active lesions, Sucralan is used as a maintenance therapy to prevent the recurrence of duodenal ulcers. This is particularly relevant for individuals who have a history of chronic ulceration and require long-term mucosal protection.

Management of Inflammation

Sucralan may be utilized to treat chronic gastritis, an inflammation of the stomach lining. It can also be applied in the management of reflux esophagitis, a condition where stomach acid flows back into the esophagus, causing irritation and discomfort. In these cases, the suspension provides a protective layer that limits contact between the sensitive esophageal and gastric mucosa and aggressive digestive fluids.

Benefits of the Suspension Form

As a 1g/5ml oral suspension, Sucralan offers specific functional advantages for gastrointestinal therapy:

  • Targeted Protection: The liquid formulation allows the active ingredient to distribute evenly across the lining of the esophagus and stomach, ensuring comprehensive coverage of affected areas.
  • Ease of Ingestion: The suspension form is often preferred for patients who have difficulty swallowing tablets or for those with esophageal inflammation where solid dosage forms might cause irritation.
  • Local Action: Sucralfate acts locally at the site of the injury. Because it is minimally absorbed into the bloodstream, its effects are concentrated on the gastrointestinal lining.
Advertisements

Eligibility and Restrictions for Use

Sucralan 1g/5ml (Sucralfate oral suspension) eligibility is strictly defined by regulatory documentation concerning age, organ function, and specific patient history.

Eligibility Scope

Population Group Eligibility Status Regulatory Context
Adults Allowed Established for short-term and maintenance use.
Pediatric Patients Not Established / Not Recommended Safety and effectiveness are not established in patients under 18 years of age.
Known Hypersensitivity Contraindicated Absolute prohibition for patients with a known reaction to sucralfate or excipients.
Chronic Renal Failure / Dialysis Use with Caution Conditional use due to risk of aluminum accumulation and toxicity (e.g., encephalopathy).
Pregnancy Use Only If Clearly Needed Classified as Pregnancy Category B; limited human data, use only when benefit clearly outweighs risk.
Lactation (Breastfeeding) Caution Advised Not known whether the drug is excreted in human milk.

Official regulatory documents confirm the medication is approved for use in the general adult population. Use is contraindicated only for hypersensitivity. Caution is advised for older adults and those with impaired gastrointestinal motility, as documented in official labeling.

Advertisements

What should I know about interactions with other medicines?

Sucralan 1g/5ml Interactions with other medicines and products

The interaction profile for Sucralan 1g/5ml is primarily structured around its nonsystemic binding to co-administered medicines within the gastrointestinal tract, which results in a reduced extent of absorption (bioavailability) for several drugs. This effect can decrease the systemic exposure of the interacting medicine.

Interactions Based on Reduced Absorption

To mitigate this effect, official regulatory documents require that several concomitant medicines be administered 2 hours prior to the Sucralan oral suspension. This separation is required to eliminate the interaction and avoid reduced absorption for medicines including:

  • Fluoroquinolone antibiotics (e.g., Ciprofloxacin, Norfloxacin, Ofloxacin)
  • Cimetidine, Digoxin, Ranitidine
  • Phenytoin, L-thyroxine, Theophylline

The regulatory label also notes reports of reduced efficacy for co-administered Warfarin, although controlled studies have yielded inconsistent results.

Pharmacodynamic and Population-Specific Risks

Sucralan interacts with other aluminum-containing products (such as certain antacids), potentially increasing the total body burden of aluminum. This specific interaction poses a heightened risk of aluminum accumulation and toxicity (e.g., osteodystrophy, encephalopathy) in patients with chronic renal failure or those receiving dialysis, due to impaired aluminum excretion. Therefore, antacids must be taken one-half hour before or after Sucralan administration.

Advertisements

Mechanism of Action

How Sucralan 1g/5ml Works: Mechanism of Action

The mechanism of Sucralan (Sucralfate) is locally active and multifaceted, combining a physical barrier effect with the augmentation of intrinsic mucosal defense. Its action is non-systemic, remaining within the gastrointestinal lumen.


Physical Barrier Formation

Sucralfate rapidly transforms in the presence of acidic gastric fluid (pH < 4) into a viscous, negatively charged polyanion gel. This gel exhibits a high and selective affinity for proteinaceous exudates exposed at the base of ulcers or erosions. This binding creates a durable, physical Ulcer-Adherent Complex . This barrier isolates the damaged tissue, reducing the chemical burden by adsorbing corrosive factors such as Pepsin A and Bile Salts, which contributes to the mitigation of further localized tissue damage.


Cytoprotective Pathways

Beyond physical shielding, Sucralfate supports intrinsic mechanisms. It stimulates the local biosynthesis of prostaglandins and physically protects essential growth factors (EGF and FGF) from proteolytic degradation. The resulting physiological effects include augmented secretion of bicarbonate and mucus—actions that contribute to the integrity of the surrounding mucosal barrier—and increased local availability of growth factors. The protected growth factors increase the rate of epithelial cell proliferation and angiogenesis (new blood vessel formation), which enhances the physiological processes of mucosal repair.

Advertisements

Dosage and Administration Information

How to Use Sucralan 1g/5ml: Official Administration Guidelines

Administration of Sucralan (sucralfate oral suspension) is restricted to the oral route only; intravenous use is explicitly prohibited. The instructions detail precise dosing and timing to structure the correct use of the medicine.


Dosing and Frequency

For acute management, the typical adult oral dose is 1 gram taken four times daily (QID). This acute regimen is generally maintained for 4 to 8 weeks or until healing is confirmed. Following the initial course, the dosage for maintenance therapy is typically adjusted to 1 gram administered twice daily (BID), a pattern used for up to one year.


Procedural Constraints

The suspension must be thoroughly shaken prior to administration. To optimize its action, the drug should be administered on an empty stomach. This is generally scheduled one hour before or two hours after meals and at bedtime. If a dose is missed, it should be taken as soon as it is remembered, unless it is close to the next scheduled dose, in which case the regular schedule should be resumed without doubling the dose.

A critical constraint involves separating the administration of Sucralan from other oral medicines. Most other drugs should be taken at least two hours before or after the sucralfate dose. Antacids must be spaced by at least 30 minutes from the Sucralan administration.


Population-Specific Guidance

Dose selection for older adults should be cautious, often starting at the low end of the dosing range, and use in patients with renal impairment requires appropriate clinical monitoring. Safety and efficacy have not been formally established for use in pediatric patients.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sucralan 1g/5ml


Evidence for Use in Active Duodenal Ulcer Treatment

Research exploring the use of Sucralan 1g/5ml oral suspension in studies examining active ulcers in the duodenum (the first part of the small intestine) primarily involves short-term randomized controlled trials (RCTs). These studies were designed to monitor outcomes related to how patients reported physical discomfort and the status of the ulcer over defined time intervals. They generally included populations with active, confirmed duodenal ulcers and assessed how ulcer status changed during the study period.

These short-term RCTs reported measurements of changes in ulcer status in the observed populations. Studies monitored the size and presence of the ulcers using endoscopy, reporting how ulcer status changed in the observed populations during the study period. Findings were often based on small populations, and research highlights changes measured only during the initial, short treatment timeframe. What remains uncertain is the applicability of these initial findings to all patients and the experience beyond the short-term study duration.


Evidence for Use in Duodenal Ulcer Recurrence Prevention

Studies have also explored the use of the oral suspension in studies examining duodenal ulcer recurrence. This research includes maintenance therapy trials and extended follow-up studies that were applied in research contexts involving fluctuating or unstable symptoms. Research exploring short-term symptom changes reported that patients observed in the studies maintained ulcer status over the defined follow-up durations. These findings describe patterns observed in the studies where the suspension was monitored over several months.


Long-Term Studies and Extended Follow-up

Research has also explored outcomes related to physical discomfort beyond the standard treatment duration. This involves studies observing responses over defined time intervals that exceed the short-term treatment period. Long-term outcomes for this suspension are not well characterized, and certainty remains low regarding the durability of any observed patterns beyond the defined study periods.


Evidence in Specific Populations

Studies have also been conducted to evaluate the suspension in specific patient groups, such as older adults and those with comorbid conditions like kidney impairment. Research describes patterns of use and findings in these populations. However, data for certain groups remain insufficient. Sample sizes were modest in studies focusing on special populations, and data for children or pregnant individuals are notably scarce or non-existent.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Sucralan 1g/5ml (FAQ)


Q: How quickly does Sucralan liquid start working to help with stomach pain?

A: According to the clinical pharmacology information, Sucralan begins forming its protective coating, like a paste, fairly quickly—typically within 1 to 2 hours after you take it. Symptom relief over time is generally tied to the healing of the ulcer, which occurs over the full course of prescribed therapy.


Q: Is it normal to feel a bit constipated after taking Sucralan?

A: Yes, constipation is the most commonly reported side effect in clinical trials, occurring in a small but notable percentage of patients (listed as 1% to 10%). While other gastrointestinal effects may occur, constipation is the most frequently experienced side effect.


Q: What are the most common mild side effects people report with Sucralan?

A: Official product information states that constipation is the most frequent complaint. Other effects reported in less than 0.5% of patients include dry mouth, nausea, vomiting, dizziness, and headache.


Q: Does Sucralan liquid taste like anything?

A: The official formulation of the oral suspension contains 'flavor' as one of the inactive ingredients. This indicates that an additive is used to influence the taste of the liquid.


Q: How long can a person typically stay on Sucralan 1g/5ml?

A: The length of time is determined by the condition being treated. The standard course for treating active duodenal ulcers is typically 4 to 8 weeks. If prescribed for long-term use to prevent ulcers from returning (maintenance therapy), the duration may be up to one year.


Q: What kind of stomach issues is Sucralan 1g/5ml not used for?

A: The medication is FDA-approved specifically for the short-term treatment and maintenance of duodenal ulcers. Use for other gastrointestinal conditions, such as simple indigestion or certain types of gastritis, falls outside of the official approved uses.


Q: What are the signs that Sucralan 1g/5ml is actually helping my condition?

A: From a clinical perspective, confirmation that a duodenal ulcer is healing is typically determined by physical assessment, such as X-ray or endoscopic examination. In terms of personal experience, symptom relief may occur as the ulcer heals.


Q: Has there been a lot of research done on the effectiveness of Sucralan 1g/5ml?

A: Yes, the effectiveness of sucralfate has been extensively studied. This includes numerous randomized controlled trials (RCTs) that have confirmed its ability to promote duodenal ulcer healing when compared against placebo and other agents like cimetidine.


Q: Is it safe to drive or operate machinery while taking Sucralan?

A: Official reports indicate that side effects such as dizziness and drowsiness have been reported. Caution may be necessary if performing tasks requiring alertness, such as driving or operating machinery.


Q: Does alcohol interact negatively with Sucralan liquid?

A: There is no specific interaction or warning for alcohol use with sucralfate listed in the official FDA label.


Q: Why do some people call Sucralan a 'stomach plaster'?

A: This term is a popular, simple way to describe the drug’s primary action. Sucralan works by chemically transforming in the acidic stomach environment to form a protective, adhesive complex that acts as a physical barrier over the damaged tissue.


Q: What are the ingredients in Sucralan 1g/5ml besides the active drug?

A: The active drug is sucralfate. The official product information lists inactive ingredients, or excipients, including colloidal silicon dioxide, FD&C Red #40, flavor, glycerin, methylcellulose, methylparaben, microcrystalline cellulose, purified water, simethicone, and sorbitol solution.


Q: How does Sucralan protect the lining of the esophagus?

A: Sucralan uses the same mechanism of action as it does in the stomach: it forms a protective coating over damaged tissues. While it is officially approved for duodenal ulcers, the coating and cytoprotective action are the same basis for its occasional use in the upper areas like the esophagus.


Q: What happens if you take too much Sucralan liquid by accident?

A: Overdose experience is very limited, and acute studies in animals did not find a lethal dose. If too much is taken, symptoms that have been rarely reported include indigestion, abdominal pain, nausea, and vomiting.


Q: Can Sucralan 1g/5ml cause changes in bowel movements other than constipation?

A: Yes. While constipation is the most common gastrointestinal side effect, less frequent reports have also included diarrhea and flatulence (gas).


Q: Is Sucralan considered an antibiotic?

A: No. According to its regulatory classification, Sucralan is categorized as an antiulcer agent or a mucosal protectant, not an antibiotic.


Q: Can Sucralan 1g/5ml cause dry mouth or drowsiness?

A: Yes, dry mouth is listed under gastrointestinal side effects, and drowsiness is listed under nervous system side effects. Both have been reported, although they are uncommon (less than 0.5% of patients in trials).


Q: Are there any dietary restrictions while taking Sucralan?

A: Official labeling primarily emphasizes the need to take the dose on an empty stomach. It also specifies timing separation from antacids. No other general dietary restrictions are listed in the official product information.


Q: Is Sucralan 1g/5ml suitable for people with diabetes?

A: The official product information suggests caution in patients who have diabetes. This is because there have been reports of hyperglycemia (high blood sugar) associated with sucralfate use.


Q: Do children ever get prescribed Sucralan 1g/5ml?

A: Official regulatory documents clearly state that the safety and effectiveness of Sucralan 1g/5ml have not been established for use in pediatric patients (children).


Q: How long after taking Sucralan can I eat food?

A: To ensure the best effectiveness, the medication must be taken on an empty stomach. This timing is defined as 1 hour before a meal or at least 2 hours after a meal.


Q: Can Sucralan 1g/5ml cause dizziness?

A: Yes, dizziness has been reported as an uncommon side effect (less than 0.5% of patients in trials), listed under nervous system disorders.


Q: What is the general success rate of Sucralan in treating duodenal ulcers?

A: Based on controlled clinical studies using the suspension, ulcer healing rates compared to placebo were observed to be 16% versus 7% at 2 weeks, 46% versus 27% at 4 weeks, and 66% versus 39% at 8 weeks.


Q: What are the signs of a serious side effect from Sucralan that requires attention?

A: The official label notes rare but serious effects. These include signs of hypersensitivity reactions, such as swelling of the face or throat, or symptoms related to a blockage (bezoar formation), such as a lack of appetite or feeling unusually full after eating only a small amount.


Q: Is there any research suggesting Sucralan helps prevent ulcers from returning?

A: Yes. Sucralan is approved for maintenance therapy specifically to reduce the risk of duodenal ulcer recurrence. Clinical trials reported that recurrence rates were lower when the suspension was used over a 4 to 12-month period compared to placebo.


Q: Does Sucralan 1g/5ml contain sugar or artificial sweeteners?

A: The official formulation of the suspension contains sorbitol solution, which is a common sugar alcohol used as a sweetener.

Advertisements

How should Sucralan 1g/5ml be stored and disposed of?

How to Store and Dispose of Sucralan 1g/5ml?

Strict adherence to official storage guidelines is required to maintain the stability of Sucralan (sucralfate) oral suspension. This medication must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be protected from excessive heat, moisture, and direct light by keeping it in the original, tightly closed, light-resistant container. A critical constraint is to keep the liquid from freezing, which can compromise the product's quality. As with all medications, it must be stored in a safe location out of the sight and reach of children.

Disposal should follow documented local regulations and guidelines. Unused or expired medication should generally be disposed of via a drug take-back program. If a program is unavailable, consult local waste management to determine the proper way to discard the medication without flushing it down the toilet or pouring it into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Sucralan 1g/5ml found in:

A-Z Index: